Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 11 of 131 for:    "Hepatitis" | "Lamivudine"

Trial of Lamivudine Treatment in HBeAg Negative Chronic Hepatitis B Patients (in Asia)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00338780
Recruitment Status : Completed
First Posted : June 20, 2006
Last Update Posted : October 30, 2006
Sponsor:
Collaborator:
GlaxoSmithKline
Information provided by:
Chinese University of Hong Kong

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Completed
Primary Completion Date : No date given
Study Completion Date : January 2005
Publications:
Chan HLY, Hui Y, Ching JYL, Leung NWY, Chan FKL, Sung JJY. Can we predict disease activity in chronic hepatitis B virus (CHB) infected patients with negative HBeAg. Gastroenterology 1999; 116: A1195
Chan HLY,Ghany MC, Lok ASF. Hepatitis B. In Schiff ER, Sorrell MF, Madrey WC, Eds. Schiff's Deseases of the LIver, 8th ed. Lippincott-Raven Publishers, New York, 1998:757-92
Chan HLY, Leung NY, Lau TCM, Wong ML, Sung JJY. Comparison of three different hepatitis B virus (HBV) DNA assays in monitoring of anti-viral therapy. Hepatology 1999 (in press)